PharmaEngine
4162.TWO
2.60 USD
0.03
+1.17%
p
Overview
Last close
2.60 usd
Market cap
368.48M usd
52 week high
3.68 usd
52 week low
2.32 usd
Target price
4 usd
Valuation
P/E
6.3444
Forward P/E
N/A
Price/Sales
4.3457
Price/Book Value
1.9749
Enterprise Value
173.59M usd
EV/Revenue
2.0446
EV/EBITDA
2.3689
Key financials
Revenue TTM
84.90M usd
Gross Profit TTM
83.27M usd
EBITDA TTM
69.23M usd
Earnings per Share
0.41 usd
Dividend
N/A usd
Total assets
179.19M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
